Agilent Technologies, a global firm focusing on life sciences and diagnostics, has launched its new Biopharma Experience Centre in Hyderabad on 29 July. The facility aims to support India’s growing biopharma sector by offering advanced lab tools, expert training, and support for developing high-quality medicines more quickly and efficiently.
The centre was inaugurated by Telangana IT and industries minister D Sridhar Babu, along with Agilent CEO Padraig McDonnell, and senior leaders from the pharma and biotech industries.
The facility will focus on helping researchers and companies develop biologics, biosimilars, and precision medicine solutions with end-to-end support, including chromatography, mass spectrometry, cell analysis, and lab informatics.
“Hyderabad has emerged as a complete healthcare and life sciences ecosystem—from drug discovery to high-quality patient care,” said Babu. “With top global pharma companies and over 230 USFDA-approved manufacturing units, Telangana is making a strong national and international impact.”
The new centre offers real-lab environments where companies can test their products for quality and compliance. It will also provide hands-on training aligned with global standards, creating opportunities for collaboration between industry, startups, and academic institutions.
“This centre shows our commitment to helping customers bring life-changing therapies to market faster. It also supports the ‘Make-in-India’ initiative by nurturing local innovation, talent, and affordable healthcare solutions,” McDonnel said.
The launch strengthens Hyderabad’s position as a major life sciences hub and is part of Agilent’s broader three-to-five-year India growth strategy, which includes expanding its presence, working closely with Indian companies, and investing in talent and infrastructure.
Agilent’s India Solution Centre in Manesar, launched earlier this year, is another part of this plan.
“Agilent is already working closely with many of India’s top biopharma companies,” McDonnell added.
The Hyderabad facility is expected to fill critical gaps in analytical capabilities and regulatory readiness, helping India take the next big leap in healthcare innovation and global pharmaceutical leadership.
